Siemens Healthineers, Novo Nordisk Aim to Boost Noninvasive Liver Test Adoption

Senticell Receives $400K NCI Grant to Advanced Lung Cancer Liquid Biopsy

AstraZeneca, Hutchmed Eye US Market for EGFR-MET Lung Cancer Combo

10x Genomics to Launch Sentira for Spatial Data Analysis

Aptadir Therapeutics Raises €40M to Develop RNA Inhibitor Drugs

Haga Bioscience, Imagenomix Partner for AI Spatial Biomarker Analysis in Cancer Pathology

AstraZeneca Invests $2B in Summit Therapeutics, Inks Clinical Trial Collab

VB Spine Nabs FDA Breakthrough Device Designation for Scoliosis Risk Test

Cepheid 13-Target Respiratory Panel Gets FDA Clearance

Astrin Biosciences, OpenLoop Health Ink Distribution Deal for Breast Cancer Rule-Out Test

Along with a POC device, the company has three tests to run on it focused on acute infections, sepsis monitoring, and the prediction of acute kidney injury.

The Cambridge, UK-based company earlier this month obtained a CE-IVD mark for its LVOne test.

As agentic AI transforms scientific work, some worry that it is evolving faster than we can answer important questions about its place in society.

The company provides genotyping, long-read whole genome sequencing, proteomics, and DNA methylation analyses for the VA-sponsored program.

The Swiss drugmaker also revealed at its annual Pharma Day that it has halted a CDK4 program.

Last week, GenomeWeb’s readers were most interested in learning about how insurance denials for MRD tests are plaguing patients amid soaring demand.

In collaboration with GeneDx, Seattle Children’s analyzed the results from 1,000 hospitalized patients who received rapid WGS as a first-tier diagnostic test.

The grant was awarded through a Japan Agency for Medical Research and Development program to fund drug development alongside venture capital firms.

Thermo Fisher will add the Evosep Eno to its portfolio of mass spectrometry products, allowing customers to purchase it directly from the company.

Combined with its FDA-cleared panel to detect Gram-positive bacterial and fungal infections, the clearance completes Qiagen's BCID portfolio on the QiaStat-Dx system.

In the deal with SciBrunch, Merck gained worldwide exclusive rights to the KRAS G12D inhibitor SPR2015.

The device uses multiple colors and keyhole-shaped droplet chambers to identify up to 15 mycobacterial targets.

Auditory nerve function assessment for all newborns with signs of hearing loss might identify those eligible for emerging gene therapies.

The device uses multiple colors and keyhole-shaped droplet chambers to identify up to 15 mycobacterial targets.

SKY-AS is designed to deliver a functional copy of the disrupted UBE3A gene to neurons, and improved motor coordination and daily function in preclinical models.

The company, which launched this summer with $6 million in seed funding, is looking to characterize the proteome of hundreds of thousands of healthy human samples.

Prime Medicine, which won an arbitration dispute with Beam Therapeutics earlier this year, now has FDA clearance to begin a Phase I/II trial of its prime editor PM647 for AATD.

The project will roll out a rapid nanopore sequencing brain tumor classification assay developed by University of Nottingham researchers.

News items for the week of September 21, 2026: Precure, Mayo Clinic, Thermo Fisher, Helix, Merck, Bionano, MSK, More

People in the news for the week of Sept. 21, 2026: Nimisha Srivastava, Glenn Bilawsky, Doug White, Vijay Singh, Carl Raimond, Michael Chen, David Horn, Charles Endweiss

New products for the week of Sept. 21, 2026: Qiagen, Helix, Countable Labs, AtlasBio, Revvity, Agilent

The company, which launched this summer with $6 million in seed funding, is looking to characterize the proteome of hundreds of thousands of healthy human samples.

Developed by Chinese researchers, tPAL deploys an engineered nanopore and enzymatic sequential digestion to achieve peptide sequencing at high resolution.

The previously unannotated enzyme system contains tandem repeats reminiscent of CRISPR enzymes, although its function remains unknown.

The Swiss company's platform tests how over 100 drugs work on patients' cells.

The settlement agreement resolves allegations from Regenxbio and UPenn accusing Sarepta of using patented tech to develop its Elevidys gene therapy.

After experts told the FDA that Galleri's benefits outweigh its risks, market analysts see a positive impact for all developers of multi-cancer detection tests.

In addition to developing AI tools, the funds will support scale-up of laboratory operations and hiring of scientific personnel.

While other firms developing CAR T-cell therapies for autoimmune conditions have come across safety issues, Kyverna reports miv-cel is well tolerated.

The firm will use the funding to develop automated extracellular vesicle isolation and purification technology for clinical-scale plasma protein biomarker studies.

While the majority of the advisory committee told FDA that they believe the benefits of Galleri outweigh its risks, they indicated that the evidence doesn't support an early detection claim

The company is testing the experimental eye drops, called licaminlimab, and their ability to treat dry eye disease within a Phase IIb/III trial.

The second-line therapy was approved based on a 46 percent response rate in a Phase I/II trial.

PsychAD Consortium investigators published nine studies based on some 6 million dorsolateral prefrontal cortex cells analyzed by single-cell transcriptomics and other methods.

A coalition of German laboratory associations warned that the cuts, proposed early this month, would be unsustainable for many of the country's labs.

Australia-based AdAlta licensed EW-001, a mesothelin-targeting CAR T-cell therapy, from Shanghai Cell Therapy Group.

The companies plan to review topline results from a Phase III trial of ulefnersen, an antisense oligonucleotide, with the FDA and other regulators.

The proposed deal combines the firms' complementary global commercial markets and technologies related to gastrointestinal testing.

Mayo Clinic Laboratories has made an investment of undisclosed size into PAH and its subsidiary LifeStrands Genomics.